166 related articles for article (PubMed ID: 21245749)
1. A novel human microplasmin fold: new perspective to thrombosis treatment.
Joison AN; Gallo FS
Blood Coagul Fibrinolysis; 2011 Apr; 22(3):236-9. PubMed ID: 21245749
[TBL] [Abstract][Full Text] [Related]
2. Thrombolytic efficacy of recombinant human microplasmin in a canine model of copper coil-induced coronary artery thrombosis.
Dommke C; Turschner O; Stassen JM; Van de Werf F; Lijnen HR; Verhamme P
J Thromb Thrombolysis; 2010 Jul; 30(1):46-54. PubMed ID: 19834783
[TBL] [Abstract][Full Text] [Related]
3. Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits.
Lapchak PA; Araujo DM; Pakola S; Song D; Wei J; Zivin JA
Stroke; 2002 Sep; 33(9):2279-84. PubMed ID: 12215599
[TBL] [Abstract][Full Text] [Related]
4. Effects of microplasmin on recovery in a rat embolic stroke model.
Rasmussen RS; Overgaard K; Pakola S; Boysen G
Neurol Res; 2008 Feb; 30(1):75-81. PubMed ID: 17588313
[TBL] [Abstract][Full Text] [Related]
5. [Microplasmin instead of a scalpel].
Heidingsfeld A; Koob V; Kräuter N; Kupka J; Rastetter A; Zündorf I; Dingermann T
Pharm Unserer Zeit; 2009; 38(4):299-300. PubMed ID: 19572347
[No Abstract] [Full Text] [Related]
6. Effect of microplasmin on the clearance of vitreous haemorrhage from an experimental model in rabbits.
Gad Elkareem AM; de Smet MD
Acta Ophthalmol; 2014 Feb; 92(1):47-50. PubMed ID: 23025384
[TBL] [Abstract][Full Text] [Related]
7. Microplasmin and tissue plasminogen activator: comparison of therapeutic effects in rat stroke model at multiparametric MR imaging.
Chen F; Suzuki Y; Nagai N; Sun X; Wang H; Yu J; Marchal G; Ni Y
Radiology; 2007 Aug; 244(2):429-38. PubMed ID: 17581889
[TBL] [Abstract][Full Text] [Related]
8. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit.
Marder VJ; Landskroner K; Novokhatny V; Zimmerman TP; Kong M; Kanouse JJ; Jesmok G
Thromb Haemost; 2001 Sep; 86(3):739-45. PubMed ID: 11583303
[TBL] [Abstract][Full Text] [Related]
9. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
[TBL] [Abstract][Full Text] [Related]
10. Highly potent fibrinolytic serine protease from Streptomyces.
Uesugi Y; Usuki H; Iwabuchi M; Hatanaka T
Enzyme Microb Technol; 2011 Jan; 48(1):7-12. PubMed ID: 22112764
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human microplasmin: production and potential therapeutic properties.
Nagai N; Demarsin E; Van Hoef B; Wouters S; Cingolani D; Laroche Y; Collen D
J Thromb Haemost; 2003 Feb; 1(2):307-13. PubMed ID: 12871505
[TBL] [Abstract][Full Text] [Related]
12. [The action of modified plasmin on the lysis of experimental thrombi].
Kizim AI; Pokrovskaia TN
Vrach Delo; 1990 May; (5):39-40. PubMed ID: 1697714
[No Abstract] [Full Text] [Related]
13. Experimental evaluation of microplasmin - an alternative to vital dyes.
Gandorfer A
Dev Ophthalmol; 2008; 42():153-159. PubMed ID: 18535388
[TBL] [Abstract][Full Text] [Related]
14. [Long-lasting activation of the fibrinolytic system in blood and its clinical application].
Bielawiec M
Pol Tyg Lek; 1969 Jan; 24(2):63-6. PubMed ID: 4240415
[No Abstract] [Full Text] [Related]
15. A targeted ferritin-microplasmin based thrombolytic nanocage selectively dissolves blood clots.
Seo J; Al-Hilal TA; Jee JG; Kim YL; Kim HJ; Lee BH; Kim S; Kim IS
Nanomedicine; 2018 Apr; 14(3):633-642. PubMed ID: 29309907
[TBL] [Abstract][Full Text] [Related]
16. [The fibrinolytic system and its activators].
Seifried E
Z Gesamte Inn Med; 1993; 48(6-7):272-82. PubMed ID: 8333223
[TBL] [Abstract][Full Text] [Related]
17. [Position and developmental trends in fibrinolytic therapy].
Markwardt F
Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(1-2):6-17. PubMed ID: 2427416
[TBL] [Abstract][Full Text] [Related]
18. [Fibrinolytic substances in thrombosis therapy].
Stamm H
Ther Ggw; 1972 Mar; 111(3):335-42. PubMed ID: 4260163
[No Abstract] [Full Text] [Related]
19. Site-specific PEGylation of micro-plasmin for improved thrombolytic therapy through engineering enhanced resistance against serpin mediated inhibition.
Kaur N; Sinha PK; Sahni G
PLoS One; 2019; 14(5):e0217234. PubMed ID: 31141522
[TBL] [Abstract][Full Text] [Related]
20. [Characteristics of the fibrinolytic system in the newborn].
Schlegel N; Hurtaud-Roux MF; Beaufils F
Ann Pediatr (Paris); 1993 Feb; 40(2):70-4. PubMed ID: 8457135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
